Progenics Pharmaceuticals To Present At Stifel Nicolaus Healthcare Conference

TARRYTOWN, N.Y., Aug. 30, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) chief executive officer Mark R. Baker will make a presentation on Thursday, September 6 at 11:30 AM ET at the 2012 Stifel Nicolaus 2012 Healthcare Conference in Boston. Mr. Baker will provide a company overview, which will be webcast live and archived for 30 days on the Events page of Progenics' website.

About Progenics

Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company dedicated to developing innovative medicines to treat disease, with a focus on cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 1 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, Relistor ®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. Relistor (methylnaltrexone bromide) subcutaneous injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness. For more information, please visit .

The Progenics Pharmaceuticals Inc. logo is available at

Additional information concerning Progenics and its business may be available in press releases or other announcements and public filings made after this announcement.

CONTACT: Amy Martini         Corporate Affairs         (914) 789-2816

company logo